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Paul C Langley, PhD 
Adjunct Professor, University of Minnesota 
 
Abstract 
On January 26, 2017, the Institute for Clinical and Economic Review (ICER) posted its final report on treatments for multiple sclerosis 
(MS) with disease modifying therapies (DMTs). The objective was to provide a modeled assessment of the effectiveness and value of 
the various DMTs against each other and supportive care. The model considered both relapsing-remitting and primary-progressive MS 
with hypothetical patient cohorts tracked from therapy initiation to death in a lifetime cost-utility framework. Recommendations were 
made for possible DMT package price discounts given benchmark willingness-to-pay cost per QALY thresholds. The purpose of this 
commentary is to assess this modeled analysis from the criteria of normal science: are the claims presented for the competing DMTs 
credible, evaluable and replicable? The review concludes that the ICER model does not meet required standards. The claims made for 
comparative effectiveness and value are non-evaluable. They are immune to failure. The review concludes that if models are to 
contribute to improving our understanding of the effectiveness and costs of DMTs then they should be evaluable in the short-term to 
allow feedback to formulary committees in a meaningful timeframe. 
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Introduction 
Over the past 12 months a number of papers and commentaries 
have been published, principally in INNOVATIONS in Pharmacy, 
which have questioned the methodological basis of much of 
what we know as cost-effectiveness or cost-utility modeling 1 2. 
These include critiques of established formulary submission 
guidelines by agencies including the National Institute for 
Health and Care Excellence (NICE) in the UK, the Pharmaceutical 
Management Agency  (PHARMAC) guidelines in New Zealand, 
the Health Information and Quality Authority (HQIA) guidelines 
for Ireland, the European Network for Health Technology 
Assessment (EUnetHTA), Recommendations for Health 
Economic Evaluations and the Academy of Managed Care 
Pharmacy (AMCP) Format for Formulary Submissions in the US 
3 4 5 6 7. At the same time, commentaries have addressed the 
role of lifetime quality adjusted life year (QALY) claims in the US 
and the limitations implicit in such claims 8 9. Critiques have also 
been presented on the policy of journal editors to publish 
lifetime cost per QALY claims and reviews of claims in selected 
disease areas 10 11 12 13 14. Attention has been given to the likely 
disruptive impact of next generation sequencing  
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on cost effectiveness modeling claims and the release of the 
second version of the Minnesota proposed Guidelines for 
Formulary Evaluation 15 16 . Most recently, commentaries have 
been published on the latest versions of guidelines for the 
Netherlands, Australia and France 17 18 19. In each case, the 
focus of the guideline has been on the construction of 
imaginary worlds. Indeed, in the case of Australia the 
requirement by the Pharmacy Benefits Advisory Committee 
(PBAC) for constructing non-evaluable cost-effectiveness claims 
has been in place for over 25 years. None of the guidelines 
addressed the issue of claims evaluation and replication.  
 
The theme that underpins these commentaries and papers is 
that health technology assessments, as characterized by 
current standards and textbooks, have missed the point in 
developing models to support cost-outcomes claims 20 . Rather 
than focusing on modeled claims that are credible, evaluable 
and replicable in a timeframe that provides rapid feedback to 
formulary committees, the focus has been on the development 
of modeled claims that have no chance of ever being evaluated. 
The view seems to be that the models are merely to ‘inform’ 
decision makers rather than supporting hypothesis testing or 
systematic observation. It is also unclear as to what ‘informed’ 
actually means and how decision makers are expected to factor 
this information into healthcare choices. 
 
The purpose of this commentary is to evaluate the latest report 
from the Institute for Clinical and Economic Review (ICER) on 
the effectiveness and value of disease modifying therapies 
(DMTs) in multiple sclerosis (MS) 21. Following from a earlier 
assessment of the ICER review of Entresto in heart failure, the 
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case is made that in persisting with a reference case 
methodology to support cost-effectiveness claims the review is 
of limited value 9. While the intent may be to ‘inform’ decision 
makers, the claims made for the cost-effectiveness of the 
competing therapies are not only non-evaluable but also non-
replicable.  They should not be considered as guides to 
formulary decisions and pricing. Rather, the claims are 
constructed from a  simulation represented by a lifetime cost-
per-QALY framework that takes its inspiration from the NICE 
reference case. Unfortunately, in constructing simulations, 
regardless of appeals that a chosen model is ’sufficient’ to 
represent a future reality, any model can be challenged and 
competing models constructed to give quite disparate claims. 
The only basis for differentiating models is through assessing 
their claims or, more simply, hypothesis testing.  As it stands, if 
cost-utility or associated lifetime claims are non-evaluable then 
we don’t know whether they are right or even if they are wrong. 
Indeed, we will never know. The claims are immune to failure. 
 
The ICER Blueprint  
If the primary objective in health technology assessments of 
competing pharmaceutical products is to inform formulary 
committees through the construction of long-term or lifetime 
models or simulations, then the ready acceptance of the NICE 
reference case by groups such as ICER, even with minor 
modifications, is quite understandable.  Indeed, there could be 
any number of competing reference cases mandated by various 
health assessment agencies. The nature of the reference case 
perspective is made quite clear in the latest draft (Version 4) of 
the Canadian guidelines: Economic evaluations are designed to 
inform decisions. As such they are distinct from conventional 
research activities, which are designed to test hypotheses 22. 
Presumably it is up to the decision makers as to which reference 
or other model they believe best ‘informs’ them in the absence 
of any attempt to evaluate the merits of competing claims 
empirically. 
 
A reference case model has been used extensively by NICE over 
the last 18 years to support reviews of products within disease 
areas as well as single product reviews 23. It has been endorsed 
by professional groups, notably the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) in both 
recommended standards for model building as well as by 
extensive educational programs 24 25. At the same time journal 
editors have been prepared to accept claims based on 
reference case models with, literally, thousands of claims 
presented through various papers yet with no apparent 
attempts to evaluate those claims or even to recognize that the 
claims are non-evaluable. 
 
In the case of ICER, the procedures for model development and 
review follow closely the NICE reference case. The key elements 
of the model, which in the case of MS was developed by the 
University of Washington (UW) School of Pharmacy Modeling 
Group, are:   
 
• defining the decision problem, through a stakeholder 
scoping exercise 
• expressing health effects as QALYs within a modeled 
cost-utility framework with a fully incremental analysis 
for the technologies being compared 
• focusing on direct medical costs 
• ensuring that the model time horizon is long enough 
to reflect all important differences in costs and 
outcomes between the technologies being compared 
• application of threshold willingness-to-pay values to 
support recommendations for product access 
The ICER reference case (following NICE) requires the decision 
model time horizon to be sufficiently long ‘to reflect all 
important differences in costs and outcomes between the 
technologies being considered’.  For NICE and the ICER, as many 
technologies have an impact over the lifetime of a patient, a 
lifetime horizon is usually considered appropriate. This is the 
case for MS. Although not explicitly stated by ICER, NICE makes 
the point that ‘analyses that limit the time horizon to periods 
shorter than the expected impact of treatment do not usually 
provide the best estimates of benefits and costs’.  
 
Application of NICE reference case standards, in the case of 
chronic disease interventions, results in a model or simulation 
that attempts to mimic the natural progression of the disease 
and the impact of competing interventions, over the patient’s 
lifetime or similar long-term time horizon. Stages of the disease 
progression are captured by, for example, a Markov process 
which tracks the hypothetical cohort of patients through the 
disease stages. Each health state is defined in terms of 
associated utilities and costs. This results in scenario driven 
claims expressed in cost-per-QALY terms. By application of a 
willingness-to-pay threshold cost-per-QALY by NICE, products 
are judged acceptable, rejected or accepted after agreement on 
a discounted price. ICER, following NICE,   also applies 
willingness-to-pay thresholds to support recommendations for 
product acceptance as well as discounting. Also, following NICE, 
there appears to be no interest  to place the model in the public 
domain so that alternative simulations can be run.  This has 
been proposed by the US Academy of Managed Care Pharmacy 
(AMCP)26.  
 
The ICER multiple sclerosis model 
The analytic framework for the MS modeling tracked a 
hypothetical cohort of patients 18 years of age and over. The 
framework tracked the patient cohort from initial diagnosis 
with an index DMT to possible relapse and therapy switching to 
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a second line DMT and, ultimately, supportive care. The 
interventions for the review of RRMS, by route of 
administration, were: 
 
• injectable (daclizumab, glatiramer acetate, interferon 
β – 1a, peginterferon β – 1a, interferon β – 1b) 
• oral (dimethyl fumarate, fingolimod, teriflunomide) 
• infused (alemtuzumab, natalizumab, ocrelizumab, 
rituximab) 
All these agents were compared across route of administration 
using both head-to-head and placebo controlled trial data, as 
well as to placebo and to each other through a network meta-
analysis. For the PPMS review, the interventions included 
ocrelizumab and rituximab, with primary comparator best 
supportive care.  
 
The principal outcome for the ICER comparative value 
assessment of the various DMTs was their projected lifetime 
cost-effectiveness in treating RRMS and PPMS. The modeled 
intervention constructed outcomes were: (i) drug costs; (ii) 
adverse event costs; (iii) total costs; (iv) quality adjusted life 
years; (v) life years; and (vi) relapses. Two Markov models were 
developed, one for relapsing remitting MS (RRMS) the other for 
progressive MS (PPMS) and with health states based on the 
Expanded Disability Status Scale (EDSS). As RRMS patients may 
progress to secondary progressive MS (SPMS) over their 
lifetime, these health states were included in the RRMS model. 
 
A natural history of MS transition matrix described the patient 
experience of MS with an estimate of the relative risk for each 
DMT therapy to derive transition probabilities between the 
health states of the model. The RRMS model consisted of 20 
health states: EDSS 0-9, EDSS 1 – 9 and death. Patients were 
distributed at baseline between the 10 RRMS health states 
according to their initial diagnosis of MS, transitioning between 
health states on a one-year cycle until death. First line 
treatment was initiated with one of the DMTs and after 
discontinuation progressed to second-line treatment and then 
supportive care. Patients could progress to death or relapse 
from any health state. As it was not feasible to model every 
possible combination of DMTs over time, an average second-
line approach was applied that aggregated second-line 
treatment over all patients. The PPMS model consisted of 10 
health states (EDSS 1- 9 including death). As in the case of the 
RRMS model, treatment naive patients were distributed among 
the health states, transitioned over a one-year cycle over a 
lifetime horizon. Discontinuation leads to best supportive care. 
Annual discontinuation probabilities were estimated from 25 of 
the 27 studies included in the base case network meta-analysis 
for EDSS progression. The annual clinical study discontinuation 
probabilities ranged from 1.9% (alemtuzumab 10 mg) to 15.5% 
(teriflunomide 7/14 mg) with 10 of the 14 DMTs estimated to 
have an annual discontinuation rate under 7%. Mortality rates 
were based on US life tables and adjusted for MS-specific EDSS 
state mortality multiplier.  
 
Annual utility values for each EDSS state were based on 
previously published estimates and scored for the EQ-5D 
instrument. Each mild/moderate relapse event was associated 
with a one-cycle disutility of 0.091 and a severe event with a 
one-cycle disutility of 0.302 (on a range of 0 – 1, where 1 is 
perfect health). Annual utility rates were estimated for RRMs 
and SPMS/PPMS separately. In the former case they ranged 
from 0.875 (EDSS = 0) to -0.1701 (EDSS = 9). In the latter they 
ranged from 0.791 (EDSS = 1) to -0.2138 (EDSS = 9). A negative 
sign indicates a utility score that is worse than death.  
 
Both models were subject to a one-way sensitivity analysis to 
capture the key drivers in the model. The models were also 
subject to a probabilistic sensitivity analysis jointly varying the 
model parameters. Possible 95% range estimates for each 
model outcome were then generated.  Model validation 
involved feedback from manufacturers on the choice of model 
assumptions, comparing the model results with other 
independently developed models and sensitivity analyses.  
 
Model results were presented for (i) total discounted costs; (ii) 
relapses; (ii) life years; and (iv) QALYs over the lifetime time 
horizon. The base case lifetime model costs for RRMS were 
approximately $333,000 for supportive care, ranging from 
$572,000 for alemtuzumab to $1.5 million for daclizumab. 
Number of projected relapses was 16.4 for supportive care, 
ranging from 10.8 for alemtuzumab to 15.6 for interferon β-1a 
to. Discounted life expectancy from age of DMT initiation was 
21.4 years for supportive care, ranging from 21.9 years for 
teriflunomide 7mg and interferon β-1a 22cg to 23.1 years for 
alemtuzumab. Discounted QALYs were 5.7 for supportive care, 
with a range from 7.8 for teriflunomide 7mg to 12.6 for 
alemtuzumab.  
 
The modeled results for PPMS patients yielded $264,300 for 
supportive care with 15.6 life years and 2.7 QALYs, compared 
to 16.1 years and 3.3 QALYs for ocrelizumab (not yet approved 
by the FDA). 
 
All scenarios were subject to one way and probabilistic 
sensitivity analyses (PSAs) to capture the impact of parameter 
uncertainty on costs and health outcomes. The PSAs involved 
jointly varying all model parameters over 5,000 simulations and 
calculating 95% credible range estimates for each model 
outcome. This yielded a probability estimate that each DMT 
was notionally cost-effective at the $150,000 per QALY 
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threshold compared to supportive care and glatiramer acetate 
20mg. 
 
ICER Conclusions 
In the case of supportive care, the threshold probabilities 
ranged from 0.0% to 99.9%, with the majority of the 15 DMTs 
reporting  ≤ 5%. In the case of glatiramer acetate 20 mg the 
probabilities ranged from 1.5% to 99.3% and with 7 of the DMTs 
≤ 10%.   
 
Estimates were also provided of the prices for each drug that 
would achieve cost-effectiveness thresholds ranging from 
$50,000 to $150,000 per QALY. Because of the accrued costs of 
second-line drugs and other care it was not possible to calculate 
a threshold price for ten of the DMTs and $50,000 and for two 
of them at a $100,000 threshold. The wholesale acquisition cost 
could not be raised enough to reach these so-called cost-
effectiveness thresholds.  
 
On the basis of these modeled results, ICER presents value-
based benchmark prices. This is the price range that would 
achieve cost-effectiveness ratios between $100,000 and 
$150,000 per QALY gained. Apart from alemtuzumab, whose 
price could be increased substantially, for most DMTs the 
discounts required to achieve both willingness to pay 
thresholds would be greater than the current average 
estimated discounted WAC except for glatiramer acetate 20mg 
and interferon β-1b 250 mcg. Average discounts from WAC for 
DMTs to achieve a $100,000 threshold ranged from 25% to 75% 
and for a $150,000 threshold a range from 94% to 58%. Finally, 
as an example, daclizumab the newest approved agent 
generates an estimate of $223,000 per QALY gained, which 
implies a discount from WAC to reach a willingness to pay 
threshold of 35% to 58%.  
 
Discussion 
It is not clear how these model results, with the various 
scenarios and comparisons to establish the impact of 
uncertainty, would be evaluated by a formulary committee. 
None of the various outcomes are presented in terms that are 
evaluable either as stand-alone or comparative claims. 
Although it is extremely doubtful if a manufacturer would 
underwrite a submission to ICER to give their ‘version’ of a 
reference case claim, there is no doubting the popularity of 
lifetime cost-utility models in the literature and the willingness 
of manufacturers to support such models. With the obvious 
caveat that we seldom find manufacturer sponsored claims that 
are not supportive of their product, there is no ‘standard’ 
reference model.  Unsurprisingly, perhaps, a significant number 
of published sponsored models point to the cost per-QALY 
estimate coming in under the $50,000 threshold with the 
attendant claim that they ‘meet’ modeling standards. Again, it 
is difficult to see how a further investment in non-evaluable 
modeled claims is expected to influence formulary committees. 
Of course, formulary committee members could always attend 
a pre-conference ISPOR workshop on lifetime models to 
appreciate better the role of non-evaluable lifetime modeled 
claims in formulary decision making. Not surprisingly perhaps, 
the extent to which health technology assessments, including 
modeled claims, are factored into health system formulary 
decisions in the US seems limited. The awareness of 
comparative effectiveness research does not translate to 
application, with concerns expressed over the need for timely 
information to support decisions 27 28 29. 
 
Models and Assumptions 
It is important to remember that, in reviewing the ICER model, 
it is not the question of whether the model structure or the 
assumptions appear ‘reasonable, but the acceptance of 
reference case approach itself. Better or more ‘realistic’ 
assumptions do not lead to a better projection; rather, different 
assumptions lead to different projections. Comparisons are 
irrelevant (e.g., comparing the final version of the ICER MS 
model with earlier versions) 30 . The fundamental issue is one of 
whether or not the model generates evaluable claims. If it does 
not, then it fails the standards of normal science. The exercise 
may be interesting, but it does nothing to further our 
understanding of the impact of competing DMTs in MS 
patients. Even so, it is of interest to consider a number of the 
key assumptions driving the model. This does not mean the 
model can be ‘improved’ but that these issues should be 
addressed if, as one might hope, the focus could shift to 
developing models with evaluable claims.  
 
Lifetime Markov Frameworks 
There is no denying the mathematical appeal of decision 
models and their more complex offspring as Markov and 
related processes. Putting on one side the issue of how the 
models are intended to generate evaluable claims, the question 
is, first, the choice of health states to map the natural course of 
the disease and, second, the transition probabilities between 
health states and, the absorbing state of death. Even within the 
reference case structure, there is no unique standard, even 
within a specific disease state, for the choice of health state, the 
time interval for the health state or the transition probabilities 
for that choice.  
 
Clearly, QALY estimates will be sensitive to the number of 
health states, the time spent in each health state over the 
projected lifetime and the utilities assigned to the time spent in 
each health state. But this is not the point. Irrespective of 
potential challenges to the model structure, the fact that a 
lifetime framework is common to all models, means they will all 
lack credibility in the absence of evaluable and replicable claims 
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for competing DMT choice and the outcomes from supportive 
care. As lifetime claims are, by construct, impossible to 
evaluate, competing models can only be defended by 
perceptions that one is more ‘realistic’ or ‘sufficient’ than 
another. A comparison that has more in common with 
epistemological debates than more practical issues of their 
relevance for formulary decisions.   
 
It is worth noting that criticisms as to the limited evidence base 
on which modeled clams in MS are based are not the first time 
these issues have been raised. Almost ten years ago, an 
Editorial in the Journal of Managed Care Pharmacy asked 
whether pharmacoeconomic modeling in MS was ‘building 
houses on sand’31 . Identified weaknesses in the evidence base 
included: (i) the short duration of RCTs to support the various 
DMTs; (ii) lack of follow-up from the RCTs; (iii) the high drop-
out rate; (iv) incomplete reporting of dropouts; and (v) 
potential elimination of treatment effect by including missing 
data. 
 
Model Input Pricing  
A weakness of cost-effectiveness modeling is that it is always 
possible to demonstrate that a product is cost-effective by a 
judicious choice of input prices, in particular unit drug costs and 
the annualized cost of treatment.  An initial market entry 
wholesale acquisition cost (WAC) may be selected to establish 
a cost-effectiveness claim. Once on formulary or accepted as 
part of a pharmacy benefit management (PBM) package – 
which may also involve unknown discounting and kickbacks – 
the manufacturer is then free to engage in a policy of regular 
price increases.  Indeed, a common gambit in pharmaceutical 
pricing is, once a product has been approved for formulary 
listing, to increase WAC on a regular basis over the life of the 
product. If sales are underperforming, the price can be raised 
to meet revenue targets. 
 
As the claims for cost-effectiveness that initially ‘convinced’ the 
formulary committee or PBM to accept the product are seldom 
(if ever) revisited over the product life cycle, the manufacturer 
has significant scope for price increases. If there is a public 
outcry, then the manufacturer can fall back on the well -tried 
defense of offering co-payment coupons. As detailed in the 
recent report from the Office of Inspector General (OIG) on the 
prevention of copayment coupon use for Medicare Part D 
drugs, the increasingly widespread use of coupons could 
impose significant costs on the part D program by encouraging 
use of more expensive brand name drugs 32 . The motivation for 
pharmaceutical manufacturers is not entirely benevolent: 
coupons are a well tried tactic to retain market share in the face 
of generic competition and to encourage greater adherence 
and persistence to enhance the revenue stream.  
 
Pricing behavior for the various DMTs in MS is no exception to 
this policy of regular price increases. Indeed, in this class of 
drugs, the pricing trend over the last 20 years has been 
particularly egregious. A recent study by Hartnung et al, 
provides estimates of the trend in annual drug costs for nine 
DMTs from 1993 to 2014 33.  Apart from the fact that DMT costs 
are two to three time bigger in the US than other countries, the 
principal finding is that DMT costs have accelerated well 
beyond inflation and substantially above rates for drugs 
observed in a similar biologic class. Annualized change in the 
cost of the nine DMTs in the evaluation ranged from 35.7% for 
glatiramer acetate to 7.9% for fingolimod. Four of the DMTs had 
annualized cost increases above 20% and four with annualized 
price increases between 13.0% and 16.8%. Natalizumab, for 
example, although being withdrawn briefly from the market 
between February 2005 and June 2006, increased in cost from 
$25,850 in 2004 to $64,233 in 2013 or an annualized increase 
of 16.2%. In terms of the overall ‘costs’ of care for commercially 
insured MS patients, a comparison of charges between 2006 to 
2011 pointed to the continuing significant impact on total costs 
of the charges associated with drug costs (52.6% in 2011) 34 . At 
the same time, the charge increase for DMTs far outstripped 
the charges for other medical services (95.7% vs. 32.4%).   
 
As far as can be ascertained, the ICER cost-utility model takes 
no account of the likely increase in DMT costs over the lifetime 
of the model cohort. DMT annual acquisition costs were 
estimated through the third quarter of 2016 as a discounted 
WAC price.  If, however, we consider the policies followed by 
manufacturers over the past ten, or even 20 years, it would be 
expected that the drug costs (and hence WAC discounted 
annualized costs) would be expected to by at least 10% and 
probably by more than 15% on an annualized basis. These 
alternative annualized cost assumptions would, presumably, 
have an impact of the cost-per-QALY estimates in the model 
and any proposals for discounting versus willingness-to-pay 
thresholds. Conversely, if, with the same willingness-to-pay 
threshold, the ICER model had been applied five years ago, the 
various DMTs would have been judged highly ‘cost-effective’ in 
terms of their annualized costs (which, again, would not have 
been adjusted for annualized cost increases). 
 
Adherence and Persistence 
The ICER model says nothing about adherence with therapy in 
MS. This is a surprising omission as the evidence from 
retrospective studies suggests that over the period to 
medication discontinuation the average medication possession 
ratio or proportion of days covered is < 0.8. This is considered 
sub-therapeutic. From a study of three western Canadian 
provinces, Evans et al report the proportion of days covered by 
DMTs ≥ 0.8 for only 76.4% (95%CI: 69.1 – 82.4%) of subjects at 
one year 35. Over the period of the study (1996-2012) the 
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combined proportion of subjects with optimal adherence was 
42.4% (95% CI: 32.5% - 52.9%). The medication possession 
ratios ranged from 0.70 to 0.77. 
 
Unadjusted estimates of MS medication persistence in the US 
by Halpern et al for the period 2000 – 2008 also point to sub-
optimal behavior. With a patient follow-up period of up to 36 
months (with patients enrolled for at least 12 months following 
the index DMT prescription) the results for four DMT therapies 
(IM interferon beta-1a, subcutaneous IFNβ-1a, IFNβ-1b and 
glatiramer acetate) give adherence percentages ranging from 
48.5 to 62.3%. Again, these are well below those rates 
considered therapeutically acceptable.  Similar patterns were 
observed from a retrospective study of DMT in Germany 36. The 
study found, for a two-year observation period an MPR of 
39.9% for four DMTs (Avonex, Betaferon, Copaxone and Rebif). 
 
Although adherence behavior is ignored, the ICER model 
attempts to capture discontinuation or persistence behavior. As 
noted, the discontinuation rates are based on the studies 
utilized in the clinical network meta-analysis. As such, they 
understate by a significant margin the MS DMT persistence 
rates reported in the literature. The Evans et al study 
referenced above estimates that, for the four DMTs average 
persistence with therapy from index prescription ranged from 
471 to 508 days (1.29 to 1.39 years) while 15.2% (CI:9.7 – 
23.1%) discontinued initial DMT therapy within 6 months and 
27.1% (CI:19.7 - 36.2%) at 12 months.  In Germany, to give a 
further example, overall persistence with DMTs at the end of 24 
months was 32.3%.   
 
The conclusion for persistence, therefore, is that only a minority 
of MS patients are persistent with their therapy at the end of 
18 months to two years, with the overall proportion likely to 
have discontinued therapy before 30 months. These patterns 
are not uncommon in a number of disease areas. That being 
said, it seems odd that the ICER would assume discontinuation 
behavior that is clearly overly optimistic. While this may be a 
reasonable assumption to ensure the model continues to be 
populated with adherent and persistent imaginary patients in 
the long term, it points to the irrelevance of lifetime models 
when the overwhelming majority of patients discontinue 
therapy in the short term or switch, for an unknown period, to 
second line DMT therapy and then supportive care).  A model 
where patients switch between DMTs over their lifetime (for 
which there is no evidence), would be the only justification for 
the ICER lifetime assumptions. Alternatively, after a few months 
of sub-optimal initial DMT therapy and early discontinuation 
the patient is presumably locked into the default condition of 
‘best supportive care’.  
 
 
Replication of Claims 
Overall, the evidence base for populating the ICER MS model is 
not only limited in the number of published studies (none of 
which attempt to replicate claims) but they are further 
constrained by their observation period. None of the phase 3 
studies of the impact on competing DMTs extends for more 
than 2 years. Rather than taking at face value claims for 
comparative DMT performance drawn from a handful of clinical 
trials, a more substantive approach would be to focus on the 
question of replication: can the claims from trials based on a 
one to two-year time horizon be replicated with feedback to 
formulary committees? Instead, we are asked to buy into a 
framework that takes these claims at face value and builds a 
non-evaluable claims framework that extends for decades into 
the future. Replication of claims is a key issue as there is ample 
evidence for the difficulty, if not impossibility, of replicating 
phase 2 and 3 randomized clinical trial (RCT) claims 37.  
 
There are a number of claims that could be assessed within a 2-
year timeframe. These would relate not only to relapse and side 
effects, where the claims are developed, possibly in a short 
term model framework, from the DMT specific RCTs. These 
would establish a base for comparative claims as well as 
presenting the opportunity to assess in more detail the 
determinants of adherence and persistence behavior. Given the 
lifetime experience of MS, it seems odd that from the evidence 
presented, the majority of that time is apparently spend, not on 
a DMT or succession of DMTs, but on ‘supportive’ care. 
 
Willingness to Pay Thresholds 
Although the ICER approach places emphasis on willingness to 
pay thresholds as a guide to decisions as to whether or not 
manufacturers should offer discounts or reduce prices, there is 
no evidence to suggest that in the US formulary committees 
apply such thresholds in pricing negotiations. Two points should 
be emphasized. First,  in the US, no one has the slightest 
interest in cost-per-QALY lifetime claims let alone cost-
effectiveness thresholds; these are an existential  
weltanschauung which, while possibly resonating with a few 
academic groups, together with single payer systems who have 
embraced the NICE reference case to support resource 
allocation, are irrelevant to treating environments and pricing. 
It might be noted, in passing,  that PHARMAC in New Zealand 
while adopting a reference case approach to product 
assessment, does not apply willingness-to-pay thresholds. 
Second, even if there were a modicum of belief in thresholds, 
they face the same objection as lifetime cost per QALY 
estimates. They are based on a model which lacks scientific 
credibility.  
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Which Simulation? 
To illustrate the concern some formulary committees might 
have in accepting results from the ICER model, a reasonable 
question is how the model outcomes might vary with changes 
in assumptions? To illustrate this possibility, it is worth noting 
the differences in estimated costs per QALY and cost per 
relapse avoided, pairwise results for DMTs compared to 
supportive care in RRMS, between the draft and final ICER 
reports. These results are shown in Table 1. 
 
The differences in the estimates from the two reports are in 
many cases quite substantial with the percentage differences in 
cost per additional QALY ranging from -44.0% for teriflunomide 
7mg to 42.4% for alemtuzumab. The range for percentage 
differences for modeled claims where the cost per QALY has 
fallen between the draft and final report range from -1.8% to -
44.0%; in those cases, where the cost has increased the range 
is from 16.3% to 42.4%. A similar picture emerges for the 
estimates cost per elapse avoided. The overall range here is 
from 30.4% for interferon β-1b 250 mcg (betaseron) to – 43.7% 
for alemtuzumab. Where the cost per relapse avoided has 
increased the range is from 0.9% to 30.4%; where the cost has 
fallen the range is from -3.2% to 43.7%. 
 
Presumably, future modifications to the model would result in 
revised estimates with each subject to a sensitivity analysis. A 
situation that could continue indefinitely with competing claims 
that ‘their model is the one that should ‘inform’ decision 
makers. Access to the model would facilitate such 
experimentation which is one reason why countries that have 
adopted a reference case model typically claim commercial 
confidentiality as the reason for not allowing public access. The 
point remains: how are we to judge one version of an MS model  
from another and how much faith do we have in the ‘final’ 
version presented in the ICER report.   
 
A Black Box Warning 
If health technology assessment groups are to persist in 
developing lifetime cost-per-QALY models, then if might be 
advisable to issue these models with the equivalent of a black 
box warning. Readers, including formulary committee 
members evaluating a reference case submission, would be 
advised: (i) that lifetime (or long-term) modeled claims are non-
evaluable; (ii) that it is entirely possible to construct a 
competing lifetime model to generate alternative claims; (iii) 
that if the lifetime model is intended to ‘inform’ decision 
makers, we have no idea if the claims are right or even if they 
are wrong; (iv) that claims for the superiority of one lifetime 
model over another based upon a review of assumptions 
regarding model structure or input parameters is a pointless 
exercise. 
 
Although not necessarily part of a black box warning, it should 
be advised that the lack of scientific credibility that attaches to 
lifetime cost-utility models also extends (i) to projections based 
on the model for the budget impact of therapies and (ii) to 
claims for possible pricing discounts based on modeled cost-
per-QALY estimates set against willingness-to-pay thresholds. 
If, of course, the model generates short term budget impact 
claims, then these can certainly be evaluated. 
 
Conclusions 
Perhaps this commentary has been too harsh in judging the 
ICER MS model by the standards of normal science. It may be 
that the ICER has never intended that claims made should be 
evaluable or replicable. Perhaps they should be seen as ‘our 
best non-evaluable projections’? Unfortunately, if this model 
for evaluating competing therapies in MS is seen as one among 
many possible projections, then the exercise loses credibility.  
Why should this model be superior to other, as yet unknown, 
projections? Are we to judge this model on its correspondence 
to what its authors and stakeholders seen see as the reality of 
treating MS? Is the model sufficient in its representation of 
reality such that the conclusions are necessarily entailed?  A 
correspondence with a future, yet unknown, reality that is 
sufficient to support its claims? A model that assumes 
manufacturers will maintain present DMT price levels? A model 
which offers a ‘superior’ vision compared to other cost-
effectiveness modeled claims for DMTs? A model which claims 
to look 20 or 30 years ahead from an index DMT prescription, 
putting to one side the pipeline of new entrant and competitor 
therapies?  
 
The fundamental issue is that in accepting a US version of the 
NICE reference case with willingness-to-pay thresholds, the 
possibility that short term models would make more sense to 
formulary committees is ignored. Rather than focusing on 
credible, evaluable and replicable claims for the DMTs, the 
model looks to an imaginary future where there is no chance of 
the claims being evaluated. There is no feedback to formulary 
committees and no appreciation of the pressing needs in MS to 
improve the evidence base for decision making. There is no 
concept of progress in understanding the impact of DMTs in 
target MS populations through hypothesis testing and 
systematic observational studies. . A more fruitful line of 
inquiry, if ICER wished to take up the challenge, would be to 
abandon the reference case. Focus instead on generating short 
term evaluable claims for competing DMTs, basing any 
recommendations for comparative product pricing and 
discounts on modeled claims that meet the standards of normal 
science: claims that are credible, evaluable and replicable. 
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Table 1 
Cost Per Additional QALY and Cost Per Relapse Avoided, Draft and Final ICER Modeled  
Results for Relapsing-Remitting Multiple Sclerosis 
 
 
Drug 
Cost per 
Additional 
QALY 
(draft)($) 
Cost per 
additional 
QALY 
(final)($) 
 
Percentage 
difference 
Cost per 
relapse 
avoided 
(draft)($) 
Cost per 
relapse 
avoided 
(final)($) 
 
Percentage 
difference 
Teriflunomide 7mg 517,764 289,970 -44.0 482,101 414,754 -14.0 
Interferon β-1a 22mcg 
(Rebif) 
432,633 341,359 -21.1 508,612 430,998 -15.3 
Interferon β-1a 30 mcg 
(Avonex)) 
352,949 331,381 -6.1 946,187 954,935 0.9 
Teriflunomide 14 mg 320,696 236,954 -26.1 432,990 400,198 -7.6 
Glatiramer acetate 20 
mg (Copaxone) 
308,808 303,302 -1.8 421,467 407,877 -3.2 
Glatiramer acetate 
20mg (Glatopa) 
204,268 194,253 -4.9 278,789 261,230 -6.3 
Interferon β-1a 44 mcg 
(Rebif) 
314,864 284,135 -9.8 445,299 418,760 -6.0 
Dimethyl fumarate 260,631 211,444 -18.9 283,560 332580 17.3 
Fingolimod 
 
270,066 238,970 -11.5 253,402 276,100 9.0 
Interferon β-1b 250 
mcg (Betaseron) 
183,617 214,355 16.7 359,069 468,100 30.4 
Interferon β-1b 250 
mcg (Extavia) 
159,412 185,369 16.3 311,736 404,801 30.0 
Peginterforon B-1a 256,255 238,321 -7.0 478,512 514,656 7.6 
Natalizumab 
 
215,180 208,987 -2.9 205,442 228,597 11.3 
Daclizumab 
 
270,373 222,782 17.6 302,209 344,719 14.1 
Alemtuzumab 
 
60,209 34,659 42.4 76,655 43,178 -43.7 
  
Source: Table 22 draft ICER report; Table 22 final ICER report  
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